Member Info for nissangtr786

This weeks trading shows how damaging the RF deal has been. Huge buys and lots of buys and the share price down. If they could somehow get rid of this RF drawdown in next RNS, get a premium placing done at say 6p, then we could see it rocketing back into the 30’s. Surely they put options so they make money when it is way above 6p?

My only hope is surely it will start going back up again at some stage? If David Budd could make this rocket to 299p, then surely James Cheek can get it to around the 12-13p it was when he joined.

I have been in since I bought a decent chunk at 64p in 2021. What a disaster this has been. Every year I think I it will surge back to those days. Last years interims hinted at a huge market for both there products and yet the share price has crashed and the new CEO who was brought into improve the share price has crashed the share price around 80% since he came.

Https://www.bmh.manchester.ac.uk/stories/genetic-testing-secondary-stroke/In May 2023, NICE produced draft guidance that recommends genotype testing if treatment with clopidogrel is being considered. Final guidance in due to be released in September 2023. We hope that this test will soon be able to be used by clinicians for this purpose.

.........

That is what annoys me more. I was waiting for that news.

The stroke NICE recommendation was actually originally due for September last year and they were confident on that.

He also told us special commissioning is happening and FDA partner news of contracts being ready to sign was coming and that was after the November presentation. Now we are nearly in April and no news on any of that. He could have come out and said it has been delayed at least. I wonder if we finally find out on everything he said that was due around December and January time in the results RNS. The worst part is I held for the FDA partner news and Stroke NICE recommendation that was before due in December 22nd and now is April 3rd. I would have sold out if they said it was delayed.

I am annoyed as he misled investors saying FDA partner news and Stroke recommendation news was due and now we are nearly in April and now we know the Stroke test that was due in December to January time, will be April 3rd now. I never expected them to delay something that was massively delayed to begin with. :(

Mean seen recently. What makes it worse is he expected so much news and delivered virtually nothing in over six months. He has made David Budd look like a productive CEO.

Presentation is on the 5th April at 10AM. I wish I never saw his profile which showed he was here to improve the share price. He must have been the worst performing new CEO in AIM history. I cannot recall any other stock having a new CEO and it continually crashed every month. What makes it worse is I now think he was brought in with a job to crash the share price as sewn recently when it went up and they released an RNS to crash it.

I reckon now it will only go up just before close before results day.

I reckon they are doing the investor presentation soon after the Stroke test news for good PR.

He joined when the share price was about 12p. He posted he was here to improve the share price and deliver better communication to shareholders. He has missed deadlines by at least 3 months and been part of radio silence while the share price collapses. RF deal has also ruined everything.

The share price probably would triple if RF were removed with a huge backer for Genedrive.

Sadly James Cheek has made David Budd look like an amazing CEO which was hard to do. I trusted James Cheek too much. Now just hoping for a miracle.

Wow a 875000 share buy. Makes no sense how it ended down.

Https://twitter.com/genedriveplc/status/1771197427652907307

Looks like a late drop instead. Next 2 weeks are big for GDR.

It would be NICE to end over 5p but need a late rally for that to happen.

That one is the Stroke one.

Https://www.nice.org.uk/guidance/indevelopment/gid-dg10054

Wow 3rd April date.

The graph is suggesting a huge surge is due going by its history.